<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Yes (indicate where provided: section/paragraph)	n/a
No antibodies were used in the present study.	N/A
	n/a
No cell lines were used in the present study.	N/A
There was no use of primary culture in the manuscript.	N/A
Vos (indicata whore provided section/paragraph)	2/2
	n/a
No experimental animals were employed in the study.	N/A
These was no opined supplied at in this research	NI/A
There was no animal experiment in this research.	N/A
T	21/2
The study did not involve the use of Model organisms.	N/A
Yes (indicate where provided: section/paragraph)	n/a
There was no use of any plants in the manuscript.	N/A
There was no experiment on microbiology in this	N/A
research.	
	Yes (indicate where provided: section/paragraph) No cell lines were used in the present study. There was no use of primary culture in the manuscript. Yes (indicate where provided: section/paragraph) No experimental animals were employed in the study. There was no animal experiment in this research. The study did not involve the use of Model organisms. Yes (indicate where provided: section/paragraph) There was no use of any plants in the manuscript. There was no experiment on microbiology in this

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Materials and methods/Paragraph 1 and Footnote/ Paragraph 4	
Provide statement confirming informed consent obtained from study participants.	No clinical patients were enrolled in the present study.	N/A
Report on age and sex for all study participants	Results/Paragraph 2 and 4 (see Table 1 and Table 2)	

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	This study was not a clinical trial.	N/A
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	We did not cited the laboratory protocol in this study.	N/A
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Materials and methods/Paragraph 1	
Randomisation	Materials and methods/Paragraph 1	
Blinding	Materials and methods/Paragraph 1	
Inclusion/exclusion criteria	Materials and methods/Paragraph 1	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Materials and methods/Paragraph 3 (see "Statistical analyses")	
Define whether data describe technical or biological replicates	The study did not involve the technical or biological replicates.	N/A
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Materials and methods/Paragraph 1 and Footnote/ Paragraph 4	•
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No experimental animals were employed in the study.	N/A
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	The data of this study was obtained from TCGA database, not based on the analysis results of specimen and field samples.	N/A
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	The study was only a basic research on the analysis of	N/A
state the authority granting approval and reference	the association between gene mutation and	,
number for the regulatory approval	chemotherapy-resistant in NSCLC.	1

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Materials and methods/Paragraph 1	
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a	l
Describe statistical tests used and justify choice of	Materials and methods/Paragraph 3		l
tests.			l

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	There were no newly created datasets in this study.	N/A
If data are publicly available, provide accession number in repository or DOI or URL.	Materials and methods/Paragraph 1	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Materials and methods/Paragraph 1	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	There was no newly generated code or software in this study.	N/A
If code is publicly available, provide accession number in repository, or DOI or URL.	No publicly available code was generated in the present study.	N/A

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/tcr-20-2568